Aerosol inhalant containing interferon alpha and terbutaline sulfate

A technology of terbutaline sulfate and aerosol inhalation agent is applied in the application field of preparing medicines for treating viral pneumonia, and can solve the problems such as viral pneumonia that have not been seen with interferon alpha and terbutaline sulfate.

Active Publication Date: 2012-04-18
BEIJING TRI PRIME GENE PHARMA CO LTD
View PDF4 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] However, there is no report on the combined use of interferon α and terbutaline sulfate in the treatment of viral pneumonia in the prior art

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Aerosol inhalant containing interferon alpha and terbutaline sulfate
  • Aerosol inhalant containing interferon alpha and terbutaline sulfate
  • Aerosol inhalant containing interferon alpha and terbutaline sulfate

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Embodiment 1: the preparation of the atomized inhalation of interferon alpha and terbutaline sulfate

[0030] The nebulized inhalation of interferon alpha and terbutaline sulfate was prepared according to the method in Table 1 below. Among them, "Anfulong" (trade name) is the recombinant human interferon α2b injection with a specification of 50 μg / ml / bottle produced by Tianjin Hualida Bioengineering Co., Ltd.; "Interfern" (trade name) is Shenyang Sansheng Pharmaceutical Co., Ltd. Recombinant human interferon α2α injection with a specification of 50 μg / ml / bottle produced by the limited liability company; Interferon α1b injection, "Boliconi" (trade name) is a terbutaline sulfate atomization solution produced by AstraZeneca with a specification of 5mg / 2ml / bottle; "PBS" is 25mmol containing 0.15mol / L NaCl / L disodium hydrogen phosphate-sodium dihydrogen phosphate buffer (pH7.0). Unless otherwise specified in the subsequent embodiments, the above trade names have the same ...

Embodiment 2

[0033] Embodiment 2: Terbutaline sulfate purity detection after mixing interferon alpha and terbutaline sulfate

[0034] The aerosolized inhalation of each interferon α and terbutaline sulfate prepared by the method of Example 1 was carried out ultrafiltration treatment with Millipore ultrafiltration centrifuge tubes with a molecular weight cut-off of 3000Da after placing the preset time, and filtered Dilute the supernatant with deionized water to the same volume as before ultrafiltration and centrifugation, then take 20 μl and put on DIKMA Platisil C 18 Reversed-phase high-performance liquid chromatography column (5 μ tm filler particle diameter, column size 4.6 * 250mm), carry out chromatographic operation under column temperature 25 ℃, mobile phase (acetonitrile-0.0065mol / L sodium octane sulfonate solution (23:77) And use acetic acid to adjust the pH value to 3.4 ± 0.2 solution) for elution, the flow rate is 1.0ml / min, and the detection wavelength is 280nm. The measurement...

Embodiment 3

[0038] Embodiment 3: Terbutaline sulfate content detection after mixing interferon alpha and terbutaline sulfate

[0039] The terbutaline sulfate reference substance (prepared by China Pharmaceutical and Biological Products Control Institute, batch number 100273-199701) was dissolved and diluted with water respectively to a concentration of 0.075, 0.150, 0.300, 0.600, 0.900 mg / ml and then according to the high-efficiency liquid phase of Example 2. Chromatographic conditions were applied to determine the peak area of ​​the main peak. Concentration (x) is carried out linear regression with peak area (y) to obtain working curve, and equation is y=8.2*10 6 x+187.68, the regression coefficient is r=0.9999.

[0040] The aerosol inhalation of each interferon α and terbutaline sulfate prepared by the method of Example 1 is carried out ultrafiltration and centrifugation according to the method of Example 2 respectively after placing the preset time, and the filtrate is used respective...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of medicinal compositions for resisting virus, and relates to an aerosol inhalant containing interferon alpha and terbutaline sulfate. The aerosol inhalant contains a therapeutically effective amount of interferon alpha, a therapeutically effective amount of terbutaline sulfate and an appropriate amount of pharmaceutic auxiliary materials; preferably, single dose of the aerosol inhalant contains 2.5 to 30 mu g of interferon alpha, 0.5 to 2 mg of terbutaline sulfate, and an appropriate amount of pharmaceutic auxiliary materials; and more preferably, single dose of the aerosol inhalant contains 10 to 20 mu g of interferon alpha, 1 to 1.5mg of terbutaline sulfate and an appropriate amount of pharmaceutic auxiliary materials. Compared with the interferon alpha or the terbutaline sulfate, the aerosol inhalant containing the interferon alpha and the terbutaline sulfate has the advantages that the effect of treating viral pneumonia can be improved obviously.

Description

technical field [0001] The invention relates to a composition of antiviral drugs and its application in the preparation of drugs for treating viral pneumonia. Background technique [0002] Viral pneumonia is a common disease in infants and young children, which seriously endangers the life and health of infants and young children. According to incomplete statistics, more than 90% of infants and young children have been infected with viral pneumonia before the age of 2, of which more than 80% of the cases are within 1 year old, the peak age of onset is 2-6 months, and severe cases can be seen in 1-6 months . The death rate of infants and young children caused by infection of viral pneumonia is 0.5%-2.0% in developed countries, up to 7% in developing countries, and it is the leading cause of infant death in my country. In addition, viral pneumonia is very contagious and reinfectious. It has been reported that family members can be infected successively, and the incidence of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/21A61K9/72A61P11/00A61P31/12A61K31/137
Inventor 周敏毅刘金毅徐晨宋文进李洁程永庆
Owner BEIJING TRI PRIME GENE PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap